C2N Diagnostics Expands Partnership With Washington University School of Medicine To Commercialize A Clinical Blood Test For Detection Of Early Alzheimer’s Disease
ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (C2N) today announced that it has expanded its partnership with Washington University School of Medicine (WUSM) in St. Louis. The objective of this collaboration is to commercialize a clinical blood test for detecting the earliest stages of Alzheimer’s disease (AD) as well as mild cognitive impairment (MCI). Under terms of the agreement, C2N has acquired the exclusive worldwide commercial license rights to a suite of technologies developed in the laboratories of Professors Randall Bateman, MD and David Holtzman, MD, in the Department of Neurology at WUSM.
Help employers find you! Check out all the jobs and post your resume.